 |
Catalyst initiates enrollment in Phase II cocaine addiction trial (Pharmaceutical Business Review) |
Catalyst Pharmaceutical Partners has initiated enrollment of patients for its 180- patient, US Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction.
More: continued here
This entry was posted on Wednesday, January 30th, 2008 and is filed under Drug Addiction. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Leave a comment